Allen Institute for Artificial Intelligence
supp.ai logo
supp.ai

Discover Supplement-Drug Interactions

Disclaimer: The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The tool is not a substitute for the care provided… (more)
Last Updated: 2 years ago

Possible Interaction: Cisplatin and Sulforaphane

supplement:

Sulforaphane

Research Papers that Mention the Interaction

Combining SF increased the cytotoxicity of CIS twofold and 5-FU tenfold, with no effects on non-cancerous stem cell viability and functions.
Conclusions Combining SF allowed lower doses of CIS or 5-FU while enhancing these drug cytotoxicities against HNSCC–CSCs, with minimal effects on healthy cells.
We investigated whether SF could enhance the chemotherapeutic effects of cisplatin (CIS) and 5-fluorouracil (5-FU) against HNSCC–CSCs, and its mechanisms of action.
British Journal of Cancer  •  2020  |  View Paper
Moreover, SFN was found to inhibit the in vivo growth of C666-1 cells and enhance the anti-tumor effects of cisplatin.
Phytomedicine : international journal of phytotherapy and phytopharmacology  •  2019  |  View Paper
We suggest that combined therapy with sulforaphane and cisplatin is efficient in suppressing tumor formation and may be a treatment option for advanced epidermal squamous cell carcinoma.
Molecular carcinogenesis  •  2018  |  View Paper
Sulforaphane synergized with cisplatin to suppress the cancer cell proliferation and enhance ovarian cancer cell apoptosis.
International journal of molecular medicine  •  2018  |  View Paper
We herein report that sulforaphane (SFN), a potent anti-cancer and well-tolerated dietary compound, inhibits cancer stem-like cell (CSC) properties and enhances therapeutic efficacy of cisplatin in human non-small cell lung cancer (NSCLC).
Oncotarget  •  2017  |  View Paper
In conclusion, combining SF with low doses of CIS or 5-FU increased cytotoxicity against SCCHN cells, while having minimal effects on normal cells.
Medical Oncology  •  2018  |  View Paper
In addition, the results demonstrated that even at the lowest concentrations (5 µM), SFN increased the sensitivity of p53‑proficient HCT‑116 cells to cisplatin.
Molecular medicine reports  •  2017  |  View Paper
Data presented in the present study clearly demonstrated that SFN significantly decreased the drug resistance to cisplatin in human CCC.
The combination of SFN with cisplatin increased cisplatin cytotoxicity, which was particularly pronounced relatively early at 36 h after treatment.
Oncology reports  •  2017  |  View Paper
Herein, co-exposure of SFN and CDDP significantly inhibited the viabilities of gastric cancer cells.
Our present study aimed to identify whether SFN could enhance the anti-cancer effects of low-dose CDDP and to determine the underlying mechanisms.
These findings not only suggested a mechanism whereby SFN enhanced the anti-cancer functions of CDDP , but also helped to regard SFN as a potential chemotherapeutic factor in gastric cancer.
Scientific reports  •  2016  |  View Paper
Although cisplatin CIS ), gemcitabine (GEM), doxorubicin, 5-flurouracil, or SF effectively induced apoptosis and prevented viability, combination of a drug with SF increased toxicity.
Molecular therapy : the journal of the American Society of Gene Therapy  •  2011  |  View Paper
Show More